Uniquely Designed Fusion Proteins for Llama Immunization

In 1993, the single domain antibody was first discovered in camels. This new category of antibody is heavy chain only, containing a single variable domain (VHH) and two constant domains (CH2, CH3). This article will outline the advantages of this unusual form of antibody and explore how the Llama IgG Fc protein is an interesting alternative to traditional antibodies when it comes to therapeutic use.

Firstly, the small size of these nanobodies allows them to reach the cryptic epitopes of targets that usually cannot be accessed by larger conventional antibodies. These antibodies are also much more stable when compared to conventional antibodies, which allows them to be delivered through oral and even ocular routes, as well as via subcutaneous and intravenous injection. If necessary, the nanobodies can also be easily coupled with cell-killing agents. Lastly, from a manufacturing point of view, nanobodies can be produced very easily from a range of hosts.

Ablynx, a Belgium-based pharmaceutical company, reported positive outcomes for its first-in-class nanobody drug caplacizumab from a phase III trial on patients with acquired thrombotic thrombocytopenic purpura (aTTP) in October 2017. This success demonstrates the great potential of nanobody drugs.

The General Process for Producing VHH

ACROBiosystems offers a unique portfolio of llama lgG Fc tagged recombinant antigens, which are exclusively designed for llama immunization.

Key Features

  • The llama IgG Fc can promote protein dimerization to enhance immunogenicity
  • High purity (see Figure 1)
  • The tag has low immunogenicity
  • Low endotoxin (less than 10 EU/mg)
  • Long half-life and good stability
  • High activity (Figure 2)

Performance of Proteins Conjugated with Llama IgG Fc Tag

Human PD-1, Llama IgG2b Fc Tag, low endotoxin (Cat. No. PD1-H5259) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Figure 1. Human PD-1, Llama IgG2b Fc Tag, low endotoxin (Cat. No. PD1-H5259) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Immobilized Human BAFF, His Tag (Cat. No. BAF-H5248) at 5 μg/mL (100 μL/well) can bind Human BCMA, Llama IgG2b Fc Tag (Cat. No. BCA-H5259) with a linear range of 0.02–0.4 ng/mL.Figure 2. Immobilized Human BAFF, His Tag (Cat. No. BAF-H5248) at 5 μg/mL (100 μL/well) can bind Human BCMA, Llama IgG2b Fc Tag (Cat. No. BCA-H5259) with a linear range of 0.02–0.4 ng/mL.

Product List of Proteins Conjugated with Llama IgG Fc Tag (Exclusive)

Molecule Cat. No. Product Description Structure
BCMA BCA-H5259 Human BCMA, Llama IgG2b Fc Tag, low endotoxin
CD19 CD9-H5250 Human CD19 (20-291), Llama IgG2b Fc Tag, low endotoxin
CD30 TN8-H5250 Human CD30, Llama IgG2b Fc Tag, low endotoxin
CD38 CD8-H5252 Human CD38, Llama IgG2b Fc Tag, low endotoxin
CD47 CD7-H5251 Human CD47, Llama IgG2b Fc Tag, low endotoxin
LAG-3 LA3-H525c Human LAG-3, Llama IgG2b Fc Tag, low endotoxin
PD-1 PD1-H5259 Human PD-1, Llama IgG2b Fc Tag, low endotoxin
PD-L1 PDL-H5250 Human PD-L1, Llama IgG2b Fc Tag, low endotoxin
Siglec-2 SI2-H525a Human Siglec-2, Llama IgG2b Fc Tag, low endotoxin
Siglec-3 CD3-H5259 Human Siglec-3, Llama IgG2b Fc Tag, low endotoxin

 

The corresponding biotinylated protein is recommended for subsequent biopanning of phage display library. This protein can be coated on Streptavidin-covered surfaces for quick, high-throughput screening.

Product List of Recommended Biotinylated Proteins

Molecule Cat. No. Product Description Structure
BCMA BC7-H82F0 Biotinylated Human BCMA / TNFRSF17 Protein, Fc Tag, Avi Tag (Avitag™)
CD30 CD0-H82E6 Biotinylated Human CD30 / TNFRSF8 Protein, Avi Tag (Avitag™)
CD38 CD8-H82E7 Biotinylated Human CD38 Protein, Avi Tag (Avitag™)
CD47 CD7-H82E9 Biotinylated Human CD47 Protein, Avi Tag (Avitag™)
LAG-3 LA3-H82F3 Biotinylated Human LAG-3, Mouse IgG2a Fc Tag, (Avitag™)
PD-1 PD1-H82E4 Biotinylated Human PD-1(recommended for biopanning)
PD-L1 PD1-H82E5 Biotinylated Human PD-L1 / B7-H1 (recommended for biopanning), Avi Tag (Avitag™)
Siglec-2 SI2-H82F8 Biotinylated Human Siglec-2, Fc Tag, (Avitag™)
Siglec-3 CD3-H82E7 Biotinylated Human Siglec-3 / CD33 Protein, Avi Tag (Avitag™)

 

ACROBiosystems

ACROBiosystems is an internationally recognized manufacturer of recombinant proteins committed to supporting cancer immunotherapy. We specialize in mammalian cell-based recombinant protein production and process development.

Our goal is to support professionals from pharmaceutical companies, CROs and research institutes who are working on the cancer immunotherapy area by providing high-quality proteins, antibodies and assay kits.

We have multiple offices and branches in North America, Europe, and Asia, and we are proud of serving customers from over 50 countries.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Nov 21, 2018 at 9:40 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2018, November 21). Uniquely Designed Fusion Proteins for Llama Immunization. News-Medical. Retrieved on August 21, 2019 from https://www.news-medical.net/whitepaper/20181109/Uniquely-Designed-Fusion-Proteins-for-Llama-Immunization.aspx.

  • MLA

    ACROBiosystems. "Uniquely Designed Fusion Proteins for Llama Immunization". News-Medical. 21 August 2019. <https://www.news-medical.net/whitepaper/20181109/Uniquely-Designed-Fusion-Proteins-for-Llama-Immunization.aspx>.

  • Chicago

    ACROBiosystems. "Uniquely Designed Fusion Proteins for Llama Immunization". News-Medical. https://www.news-medical.net/whitepaper/20181109/Uniquely-Designed-Fusion-Proteins-for-Llama-Immunization.aspx. (accessed August 21, 2019).

  • Harvard

    ACROBiosystems. 2018. Uniquely Designed Fusion Proteins for Llama Immunization. News-Medical, viewed 21 August 2019, https://www.news-medical.net/whitepaper/20181109/Uniquely-Designed-Fusion-Proteins-for-Llama-Immunization.aspx.

Other White Papers by this Supplier